|
1
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Eroles P, Bosch A, Pérez-Fidalgo JA and
Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and
signaling pathways. Cancer Treat Rev. 38:698–707. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Schnitt SJ: Classification and prognosis
of invasive breast cancer: From morphology to molecular taxonomy.
Mod Pathol. 23 (Suppl 2):S60–S64. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sørlie T: Molecular portraits of breast
cancer: Tumour subtypes as distinct disease entities. Eur J Cancer.
40:2667–2675. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Radisky ES and Radisky DC: Matrix
metalloproteinase-induced epithelial-mesenchymal transition in
breast cancer. J Mammary Gland Biol Neoplasia. 15:201–212.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Garg M: Epithelial-mesenchymal
transition-activating transcription factors-multifunctional
regulators in cancer. World J Stem Cells. 5:188–195.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Hu QP, Kuang JY, Yang QK, Bian XW and Yu
SC: Beyond a tumor suppressor: Soluble E-cadherin promotes the
progression of cancer. Int J Cancer. 138:2804–2812. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wong KK: DNMT1: A key drug target in
triple-negative breast cancer. Sem Cancer Biol, May 24, 2020
(Online ahead of print).
|
|
13
|
Chen Z, Zhang D, Yue F, Zheng M, Kovacevic
Z and Richardson DR: The iron chelators Dp44mT and DFO inhibit
TGF-β-induced epithelial-mesenchymal transition via up-regulation
of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem.
287:17016–17028. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu W, Xing F, Iiizumi-Gairani M, Okuda H,
Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo YY, et al:
N-myc downstream regulated gene 1 modulates Wnt-β-catenin
signalling and pleiotropically suppresses metastasis. EMBO Mol Med.
4:93–108. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Logan J and Bourasssa MW: The rationale
for a role for diet and nutrition in the prevention and treatment
of cancer. Eur J Cancer Prev. 27:406–410. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bezerra DP, Pessoa C, de Moraes MO,
Saker-Neto N, Silveira ER and Costa-Lutufo LV: Overview of the
therapeutic potential of piplartine (piperlongumine). Eur J Pharm
Sci. 48:453–463. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Prasad S and Tyagi A: Historical spice as
a future drug: Therapeutic potential of piperlongumine. Curr Pharm
Des. 22:4151–4159. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tripathi SK and Biswal BK: Piperlongumine,
a potent anticancer phytotherapeutic: Perspectives on contemporary
status and future possibilities as an anticancer agent. Pharmacol
Res. 156(104772)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong
XX, Cheng K, Yu SB, Shi Z, Yu AC and Chen XQ: Piperlongumine
selectively kills glioblastoma multiforme cells via reactive oxygen
species accumulation dependent JNK and p38 activation. Biochem
Biophy Res Commun. 437:87–93. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Roh JL, Kim EH, Park JY, Kim JW, Kwon M
and Lee BH: Piperlongumine selectively kills cancer cells and
increases cisplatin antitumor activity in head and neck cancer.
Oncotarget. 5:9227–9238. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Park JA, Na HH, Jin HO and Kim KC:
Increased expression of FosB through reactive oxygen species
accumulation functions as pro-apoptotic protein in piperlongumine
treataed MCF7 breast cancer cells. Mol Cells. 42:884–892.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen D, Ma Y, Li P, Liu M, Fang Y, Zhang
J, Zhang B, Hui Y and Yin Y: Piperlongumine induces apoptosis and
synergizes with doxorubicin by inhibiting the JAK2-STAT3 pathway in
triple-negative breast cancer. Molecules. 24(2338)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shrivastava S, Kulkarni P, Thummuri D,
Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S:
Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR
signaling axis to induce caspase-dependent apoptosis in human
triple-negative breast cancer cells. Apoptosis. 19:1148–1164.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ashfaq UA, Riaz M, Yasmeen E and Yousaf
MZ: Recent advances in nanoparticle-based targeted drug-delivery
systems against cancer an role of tumor microenvironment. Crit Rev
Ther Drug Carrier Syst. 34:317–353. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fofaria NM, Qhattal HS, Liu X and
Srivastava SK: Nanoemulsion formulations for anti-cancer agent
piplartine-characterization, toxicological, pharmacokinetics and
efficacy studies. Int J Pharm. 498:12–22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
de Lima Moreira F, Habenschus MD, Barth T,
Marques LM, Pilon AC, da Silva Bolzani V, Vessecchi R, Lopes NP and
de Oliveira AR: Metabolic profile and safety of piperlongumine. Sci
Rep. 6(33646)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Majumdar D, Jung KH, Zhang H, Nannapaneni
S, Wang X, Amin AR, Chen Z, Chen ZG and Shin DM: Luteolin
nanoparticle in chemoprevention: In vitro and in vivo anticancer
activity. Cancer Prev Res (Phila). 7:65–73. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rad JG and Hoskin DW: Delivery of
apoptosis-inducing piperine to triple-negative breast cancer cells
via co-polymeric nanoparticles. Anticancer Res. 40:689–694.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Danhier F, Ansorena E, Silva JM, Coco R,
Le Breton A and Préat V: PLGA-based nanoparticles: An overview of
biomedical applications. J Control Release. 161:505–522.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yang Q, Liao J, Deng X, Liang J, Long C,
Xie C, Chen X, Zhang L, Sun J, Peng J, et al: Anti-tumor activity
and safety evaluation of fisetin-loaded methoxy poly(ethylene
glycol)-poly(epsilon-caprolactone) nanoparticles. J Biomed
Nanotechnol. 10:580–591. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tester AM, Ruangpanit N, Anderson RL and
Thompson EW: MMP-9 secretion and MMP-2 activation distinguish
invasive and metastatic sublines of a mouse mammary carcinoma
system showing epithelial-mesenchymal transition traits. Clin Exp
Metastasis. 18:553–560. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kubiatowski T, Jang T, Lachyankar MB,
Salmonsen R, Nabi RR, Quesenberry PJ, Litofsky NS, Ross AH and
Recht LD: Association of increased phosphatidylinositol 3-kinase
signaling with increased invasiveness and gelatinase activity in
malignant gliomas. J Neurosurg. 95:480–488. 2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and
Weiss SJ: Canonical Wnt signaling regulates Slug activity and links
epithelial-mesenchymal transition with epigenetic breast cancer 1,
early onset (BRCA1) repression. Proc Natl Acad Sci USA.
109:16654–16659. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940.
2004.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nagi C, Guttman M, Jaffer S, Qiao R, Keren
R, Triana A, Li M, Godbold J, Bleiweiss IJ and Hazan RB: N-cadherin
expression in breast cancer: Correlation with an aggressive
histologic variant-invasive micropapillary carcinoma. Breast Cancer
Res Treat. 94:225–235. 2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chao YL, Shepard CR and Wells A: Breast
carcinoma cells re-express E-cadherin during mesenchymal to
epithelial reverting transition. Mol Cancer. 9(179)2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu
Y, Zhang CY, Zen K and Gu H: Slug-upregulated miR-221 promotes
breast cancer progression through suppressing E-cadherin
expression. Sci Rep. 6(25798)2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and
N-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8(118)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Bailey KL, Agarwal E, Chowdhury S, Luo J,
Brattain MG, Black JD and Wang J: TGFβ/Smad3 regulates
proliferation and apoptosis through IRS-1 inhibition in colon
cancer cells. PLoS One. 12(e0176096)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gao F, Zhou L, Li M, Liu W, Yang S and Li
W: Inhibition of ERKs/Akt-mediated c-Fos expression is required for
piperlongumine-induced cyclin D1 downregulation and tumor
suppression in colorectal cancer cells. Onco Targets Ther.
13:5591–5603. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ross KR, Corey DA, Dunn JM and Kelley TJ:
SMAD3 expression is regulated by mitogen-activated protein kinase
kinase-1 in epithelial and smooth muscle cells. Cell Signal.
19:923–931. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM and
Pardee AB: Drg-1 as a differentiation-related, putative metastatic
suppressor gene in human colon cancer. Cancer Res. 60:749–755.
2000.PubMed/NCBI
|
|
45
|
Han LL, Hou L, Zhou MJ, Ma ZL, Lin DL, Wu
L and Ge YL: Aberrant NDRG1 methylation associated with its
decreased expression and clinicopathological significance in breast
cancer. J Biomed Sci. 20(52)2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Graff JR, Gabrielson E, Fujii H, Baylin SB
and Herman JG: Methylation patterns of the E-cadherin 5' CpG island
are unstable and reflect the dynamic, heterogeneous loss of
E-cadherin expression during metastatic progression. J Biol Chem.
275:2727–2732. 2000.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Graff JR, Herman JG, Lapidus RG, Chopra H,
Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB:
E-cadherin expression is silenced by DNA hypermethylation in human
breast and prostate carcinomas. Cancer Res. 55:5195–5199.
1995.PubMed/NCBI
|
|
48
|
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H,
Welsh W and Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate
inhibits DNA methyltransferase and reactivates methylation-silenced
genes in cancer cell lines. Cancer Res. 63:7563–7570.
2003.PubMed/NCBI
|
|
49
|
Jones PA, Issa JP and Baylin S: Targeting
the cancer epigenome for therapy. Nat Rev Genet. 17:630–641.
2016.PubMed/NCBI View Article : Google Scholar
|
